

# Nathan P Staff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/842369/publications.pdf>

Version: 2024-02-01

89  
papers

5,007  
citations

117571

34  
h-index

98753

67  
g-index

90  
all docs

90  
docs citations

90  
times ranked

6743  
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized <scp>placeboâ€controlled</scp> phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2022, 65, 291-302.	1.0	41
2	Update on Toxic Neuropathies. <i>Current Treatment Options in Neurology</i> , 2022, 24, 203-216.	0.7	2
3	Genetic Reduction of Mitochondria Complex I Subunits is Protective against Cisplatin-Induced Neurotoxicity in <i>Drosophila</i> . <i>Journal of Neuroscience</i> , 2022, 42, 922-937.	1.7	20
4	320 Genetic Compensation as a mechanism underlying patients with Rare ALS. <i>Journal of Clinical and Translational Science</i> , 2022, 6, 57-57.	0.3	0
5	Comparative Performance of Different Respiratory Test Parameters for Detection of Early Respiratory Insufficiency in Patients With ALS. <i>Neurology</i> , 2022, 99, .	1.5	2
6	Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). <i>Supportive Care in Cancer</i> , 2021, 29, 833-840.	1.0	23
7	Proteomic analysis of human iPSC-derived sensory neurons implicates cell stress and microtubule dynamics dysfunction in bortezomib-induced peripheral neurotoxicity. <i>Experimental Neurology</i> , 2021, 335, 113520.	2.0	6
8	Alterations of mesenchymal stromal cells in cerebrospinal fluid: insights from transcriptomics and an ALS clinical trial. <i>Stem Cell Research and Therapy</i> , 2021, 12, 187.	2.4	8
9	Academic physician specialistsâ€™™ views toward the unproven stem cell intervention industry: areas of common ground and divergence. <i>Cytotherapy</i> , 2021, 23, 348-356.	0.3	9
10	Nelarabine-Induced Myelotoxicity. <i>Neurology</i> , 2021, 96, 175-176.	1.5	5
11	Small Fiber Neuropathy Incidence, Prevalence, Longitudinal Impairments, and Disability. <i>Neurology</i> , 2021, 97, e2236-e2247.	1.5	18
12	MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. <i>Neurodegenerative Disease Management</i> , 2021, 11, 431-443.	1.2	16
13	Academic Physician Specialistsâ€™™ Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapiesâ€™™ A Qualitative Analysis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3086-3096.	1.4	4
14	Neuronal Protection for Chemotherapy Neuropathy Prevention?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 3-4.	3.0	2
15	Modeling chemotherapy induced peripheral neuropathy (CIPN) in vitro: Prospects and limitations. <i>Experimental Neurology</i> , 2020, 326, 113140.	2.0	26
16	Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. <i>Experimental Neurology</i> , 2020, 324, 113121.	2.0	118
17	Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. <i>Muscle and Nerve</i> , 2020, 62, 156-166.	1.0	60
18	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	32

#	ARTICLE	IF	CITATIONS
19	Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy. <i>Brain Communications</i> , 2020, 2, fcaa050.	1.5	6
20	The NEALS primary lateral sclerosis registry. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 74-81.	1.1	5
21	Postsurgical Neuropathy: A Descriptive Review. <i>Mayo Clinic Proceedings</i> , 2020, 95, 355-369.	1.4	8
22	The current state of electrocorticography-based brain-computer interfaces. <i>Neurosurgical Focus</i> , 2020, 49, E2.	1.0	60
23	Peripheral Neuropathies Due to Vitamin and Mineral Deficiencies, Toxins, and Medications. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1280-1298.	0.4	2
24	Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. <i>Supportive Care in Cancer</i> , 2019, 27, 3729-3737.	1.0	53
25	Dominant collagen XII mutations cause a distal myopathy. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1980-1988.	1.7	24
26	Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S63-S73.	1.4	32
27	Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S26-S39.	1.4	74
28	Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S6-S12.	1.4	37
29	DNA methylation patterns in human iPSC-derived sensory neuronal differentiation. <i>Epigenetics</i> , 2019, 14, 927-937.	1.3	9
30	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. <i>Mayo Clinic Proceedings</i> , 2019, 94, 892-905.	1.4	112
31	On the Association Between Fluoroquinolones and Neuropathy. <i>JAMA Neurology</i> , 2019, 76, 753.	4.5	7
32	Clinical spectrum of neuropathy after primary total knee arthroplasty: A series of 54 cases. <i>Muscle and Nerve</i> , 2019, 59, 679-682.	1.0	9
33	Association between ALS and retroviruses: evidence from bioinformatics analysis. <i>BMC Bioinformatics</i> , 2019, 20, 680.	1.2	7
34	Case-Based Learning in Translational Biomedical Research Education: Providing Realistic and Adaptive Skills for Early-Career Scientists. <i>Academic Medicine</i> , 2019, 94, 213-216.	0.8	10
35	NurOwn, phase 2, randomized, clinical trial in patients with ALS. <i>Neurology</i> , 2019, 93, e2294-e2305.	1.5	95
36	A treatable hypertrophic neuropathy. <i>Practical Neurology</i> , 2019, 19, 80-82.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Long-term neurotoxicity in women with breast cancer.. Journal of Clinical Oncology, 2019, 37, e23089-e23089.	0.8	2
38	Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 636-641.	0.9	109
39	Somatotopic heat pain thresholds and intraepidermal nerve fibers in health. Muscle and Nerve, 2018, 58, 509-516.	1.0	4
40	Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clinic Proceedings, 2018, 93, 1617-1628.	1.4	227
41	Chemotherapy-induced peripheral neuropathy: A current review. Annals of Neurology, 2017, 81, 772-781.	2.8	506
42	A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Supportive Care in Cancer, 2017, 25, 3407-3416.	1.0	45
43	Association of Long-term Opioid Therapy With Functional Status, Adverse Outcomes, and Mortality Among Patients With Polyneuropathy. JAMA Neurology, 2017, 74, 773.	4.5	80
44	Genome editing technologies and their potential to treat neurologic disease. Neurology, 2017, 89, 1739-1748.	1.5	6
45	Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurology, 2017, 74, 1216.	4.5	244
46	Safety and efficacy of transplantation of nurown (autologous mesenchymal stromal cells secreting) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 trial. Cytotherapy, 2017, 19, S23.	0.3	3
47	Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 192-197.	1.2	22
48	Fit for Chemo: Nerves May Thank You. Journal of the National Cancer Institute, 2017, 109, djw208.	3.0	1
49	Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE, 2017, 12, e0182002.	1.1	65
50	Adult-onset respiratory insufficiency, scoliosis, and distal joint hyperlaxity in patients with multimimicore disease due to novel <i>Megf10</i> mutations. Muscle and Nerve, 2016, 53, 984-988.	1.0	18
51	The immune system continues to knock at the ALS door. Neuromuscular Disorders, 2016, 26, 335-336.	0.3	3
52	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Supportive Care in Cancer, 2016, 24, 5059-5068.	1.0	67
53	Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology, 2016, 87, 2230-2234.	1.5	93
54	Variability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 781.	4.5	0

#	ARTICLE	IF	CITATIONS
55	Neurotoxicity to DRG neurons varies between rodent strains treated with cisplatin and bortezomib. <i>Journal of the Neurological Sciences</i> , 2016, 362, 131-135.	0.3	23
56	Neuropathies after surgery: Anatomical considerations of pathologic mechanisms. <i>Clinical Anatomy</i> , 2015, 28, 678-682.	1.5	22
57	A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting <sc>P</sc>hase <sc>I</sc> human trials. <i>Transfusion</i> , 2015, 55, 1013-1020.	0.8	25
58	Magnetic resonance imaging abnormalities of peripheral nerve and muscle are common in amyotrophic lateral sclerosis and share features with multifocal motor neuropathy. <i>Muscle and Nerve</i> , 2015, 52, 137-139.	1.0	30
59	Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. <i>Journal of the Neurological Sciences</i> , 2015, 349, 124-128.	0.3	55
60	Autonomic system and amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2015, 51, 676-679.	1.0	68
61	Impairments and comorbidities of polyneuropathy revealed by population-based analyses. <i>Neurology</i> , 2015, 84, 1644-1651.	1.5	77
62	Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3416-3422.	0.8	216
63	A comparison of the natural history of oxaliplatin- and paclitaxel-induced neuropathy (NCCTG N08C1.) Tj ETQq1 1 0.784314 1gBT /Ov	0.8	10
64	Chronic meralgia paresthetica and neurectomy. <i>Neurology</i> , 2014, 82, 1551-1555.	1.5	43
65	Breaking Down Translation Barriers: Investigator's Perspective. <i>Science Translational Medicine</i> , 2014, 6, 252cm7.	5.8	12
66	Peripheral Neuropathy Due to Vitamin Deficiency, Toxins, and Medications. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2014, 20, 1293-1306.	0.4	40
67	Ipsilateral Inflammatory Neuropathy After Hip Surgery. <i>Mayo Clinic Proceedings</i> , 2014, 89, 454-461.	1.4	29
68	Postsurgical Inflammatory Neuropathy Should Be Considered in the Differential Diagnosis of Diaphragm Paralysis after Surgery. <i>Anesthesiology</i> , 2014, 120, 1057-1057.	1.3	3
69	Assessing Decreased Sensation and Increased Sensory Phenomena in Diabetic Polyneuropathies. <i>Diabetes</i> , 2013, 62, 3677-3686.	0.3	59
70	Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. <i>NeuroToxicology</i> , 2013, 39, 124-131.	1.4	88
71	An automated climbing apparatus to measure chemotherapy-induced neurotoxicity in <i>Drosophila melanogaster</i> . <i>Fly</i> , 2013, 7, 187-192.	0.9	20
72	Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. <i>Brain</i> , 2012, 135, 3074-3088.	3.7	103

#	ARTICLE	IF	CITATIONS
73	MRI and PET imaging discordance in neurosarcoidosis. <i>Neurology</i> , 2012, 79, 1070-1070.	1.5	25
74	A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. <i>Muscle and Nerve</i> , 2012, 46, 964-970.	1.0	21
75	Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons. <i>Neurobiology of Disease</i> , 2011, 41, 661-668.	2.1	252
76	<i>Drosophila melanogaster</i> : A new model to study cisplatin-induced neurotoxicity. <i>Neurobiology of Disease</i> , 2011, 43, 330-337.	2.1	44
77	Neuronal intracellular transport and neurodegenerative disease. <i>Neurology</i> , 2011, 76, 1015-1020.	1.5	12
78	Etiologic investigation of ischemic stroke in young adults. <i>Neurology</i> , 2011, 77, 1932-1933.	1.5	1
79	Metastatic lobular breast adenocarcinoma presenting as cauda equina syndrome. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 75-78.	1.4	4
80	Hypertrophic nerves producing myelopathy in fulminant CIDP. <i>Neurology</i> , 2010, 75, 750-750.	1.5	12
81	Post-surgical inflammatory neuropathy. <i>Brain</i> , 2010, 133, 2866-2880.	3.7	203
82	Multiple Sclerosis With Predominant, Severe Cognitive Impairment. <i>Archives of Neurology</i> , 2009, 66, 1139-43.	4.9	79
83	Form and Function of on-off Amacrine Cells in the Amphibian Retina. <i>Journal of Neurophysiology</i> , 2006, 95, 3171-3190.	0.9	19
84	Intracellular correlate of EPSP-spike potentiation in CA1 pyramidal neurons is controlled by GABAergic modulation. <i>Hippocampus</i> , 2003, 13, 801-805.	0.9	59
85	Psychostimulant-Induced Plasticity of Intrinsic Neuronal Excitability in Ventral Subiculum. <i>Journal of Neuroscience</i> , 2003, 23, 9937-9946.	1.7	34
86	Dendritic spikes as a mechanism for cooperative long-term potentiation. <i>Nature</i> , 2002, 418, 326-331.	13.7	582
87	Action Potential Bursting in Subicular Pyramidal Neurons Is Driven by a Calcium Tail Current. <i>Journal of Neuroscience</i> , 2001, 21, 3312-3321.	1.7	107
88	Structure and functional connections of presynaptic terminals in the vertebrate retina revealed by activity-dependent dyes and confocal microscopy. <i>Journal of Comparative Neurology</i> , 2001, 437, 129-155.	0.9	15
89	Resting and Active Properties of Pyramidal Neurons in Subiculum and CA1 of Rat Hippocampus. <i>Journal of Neurophysiology</i> , 2000, 84, 2398-2408.	0.9	185